anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
While robotic and laparoscopic surgeries are both minimally invasive in nature, they are intrinsically different approaches and it is critical to understand outcome differences between the two. Studies evaluating pain outcomes and opioid requirement differences between the robotic and laparoscopic colorectal resections are conflicting and often underpowered. In this retrospective, cohort study, we compare postoperative opioid requirements, reported as morphine milligram equivalents (MME), postoperative average and highest pain scores across postoperative days (POD) 0-5, and return to work in patients who underwent robotic versus laparoscopic colorectal resections. The sample size was selected based on power calculations. Daily pain scores and MME were used as outcomes in linear mixed effect models with unstructured covariance between time points. Propensity score weighting was used to adjust for imbalances. Patients in the robotic group required significantly less opioids as measured by MME on all postoperative days (p = 0.004), as well as lower average and highest daily pain scores for POD 0-5 (p = 0.02, and p = 0.006, respectively). In a linear mixed-effects model, robotic resections were associated with a decrease in average pain scores by 0.36 over time (p = 0.03) and 35 fewer MME requirements than the laparoscopic group (p = 0.0004). Patients in the robotic arm had earlier return to work (2.1 vs 3.8 days, p = 0.036). The robotic approach to colorectal resections is associated with significantly less postoperative pain, decreased opioid requirements, and earlier return to work when compared to laparoscopy, suggesting that the robotic platform provides important clinical advantages over the laparoscopic approach.
Disclosed are triazole compounds, and a preparation method thereof and use. The triazole compounds in the present invention have good LPAR1 antagonistic activity and selectivity, low toxicity, and good metabolic stability, and can be used for preventing or treating the LPAR1-related disease or disorder. The IC 50 value of some compounds in the present invention can be below 300 nM, even 50 nM. All the compounds in the present invention have good safety, and the range of CC 50 thereof can be greater than 200 µM. The compounds in the present invention have good metabolic stability in human, fancy rats, and house mice. The preparation method for the compounds in the present invention is simple, requires mild operation conditions, has high product yield, and is suitable for industrial production.
Taking Care of Us involves seven sessions delivered via Zoom to couples over approximately two months. Sessions last approximately 45-60 minutes and are delivered by a trained interventionist. The program is a communication-based, relationship-focused intervention that is strengths-based and fosters new skills to support couples managing heart failure. The goals of the program are to 1) target the couple with heart failure as a team; 2) increase shared appraisal within the couple; 3) improve communication skills within the couple; 4) improve collaboration within the couple and dyadic management of heart failure; 5) improve confidence within the couple; and 6) improve both individual and dyadic health and well-being.
The invention relates to a beautifying method and a product especially pointed to eye region. Before the product is used, the inner layer surface of an herb poke is required to be drenched by water, after being heated or refrigerated, the product is taken on the eye region by hot application or cold application. The related product of the beautifying method for the eye region is an herb poke, herb powder suitable for mixing with the water and suitable for the hot application or cold application is filled inside the herb poke. The inner layer surface of the herb poke close to the skin is made of material with good air permeability and good water permeability; and the outer layer surface not close to the skin is made of material without air permeability and water permeability. The herb molecule inside the poke can be fully acted on the skin around the eye region under the synergic function of heating power, moisture, or low temperature. And the purpose of eliminating the eye strain and the preventing the cutis laxa can be attained.
In the hypnosis-based intervention, patients (in groups of approximately 10 participants) will participate in 8 weekly sessions (2 hours each) during which they will benefit from guided hypnosis exercises, and learn how to implement self-hypnosis. They will also receive a CD with hypnosis exercises for home practice. At-home practice is encouraged between sessions.
FIELD: experimental medicine. SUBSTANCE: as distinct from the prototype, where wound surface is closed with porous film of synthetic flexible materials with immobilized drugs, with exudate and decomposition products of tissues accumulating under the film, and removal of bandage results in damage to granulations, the offered method includes placing of wound surface into 0.9% solution of common salt with periodic replacement of solution (2-4 times a day). Solution of sodium chloride promotes active cleaning of wound, stimulates regeneration of integument. Solution may be used as base for water-soluble drugs. Replacement of solution does not result in damage to granulations, it is painless and easily realized. Cost of 0.9% solution of sodium chloride and its simple preparation compare favorably of the offered method with the prototype. EFFECT: higher efficiency of the offered method of temporary closing of wounds and preparation of wound surface for epidermatoplasty, its simplification and reduced cost.
Women in the intervention arm will 3 times receive a three hours work shop with introduction to meditation and mindfulness over a 7 week period from a certified meditation instructor. Questionnaires before and after the intervention.
The main objective is the improvement of the diagnosis of rare genetic diseases. The investigator lab is expert for diagnosis of some rare diseases such as neurodevelopmental disorder, albinism, cystic fibrosis and congenital heart defect. Actually with implementation of high-throughput sequencing for diagnosis, a high number of genetic variants are found and need to be interpretated. The ACMG classification is used to classify variants with argument of variant frequency, predicted effect on protein and in-silico prediction. Functional evidence is a strong argument to help classify VOUS. The investigators propose the use of RNA-Seq, minigene and luciferase assay for study of VOUS to bring argument to classify them as benign or pathogenic.
In the United States, 10% of women choose an intrauterine device (IUD) for contraception. With typical use, unintended pregnancy rates in the first year of IUD contraception are 0.8% (Copper T) and 0.2% (LNG). It is known that long-acting, reversible contraception methods reduce the long-term cost of unintended pregnancies. A common deterrent to intrauterine contraception is the fear of pain during placement. Methods of pain relief during IUD insertion must be fast-acting but have minimal sedation. There have been many attempts to find effective pain relief during IUD placement. Neither ibuprofen nor naproxen have been shown to be effective in reducing pain. Misoprostol has been used to increase cervical ripening; however, pain was not decreased, and side effects of nausea and vomiting were increased. Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) that works by reversibly inhibiting cyclooxygenase-1 and 2.Time to peak plasma concentration ketorolac in the oral form is 44 minutes. Studies have shown that one dose of ketorolac can be as potent as morphine. Ketorolac is also well established for pain control in the immediate post-operative period. A recent study showed that intramuscular ketorolac wais effective in reducing pain after IUD insertion, but 20% of the participants reported that after the procedure, the injection site was as painful as the IUD placement. The current study was designed to evaluate if there is reduced pain during IUD placement using oral ketorolac 40-60 minutes before the procedure compared to a placebo.
Participants with chronic liver disease and classified as Child-Pugh Grade C had a score of 10-15 (out of 15) which correlates with decompensated liver disease. Each participant received one sublingual tablet of Suboxone® (2mg buprenorphine with 0.5 mg naloxone) on Day 1.
The present invention relates generally to medical systems and methods and more particularly to substance delivering implants and methods for treating a broad range of disorders including but not limited to sinusitis and other ear, nose and throat disorders. The system includes a guide catheter for insertion into the nose and a balloon catheter comprising a balloon. The balloon catheter is advanceable through the guide catheter to a location where the balloon is within the Eustachian tube and inflatable to enlarge the Eustachian tube. It is thereafter removable leaving the guide catheter in place. The system also includes a device for delivering a substance to a location within the body of a human or animal subject to diagnose or treat a disorder. The device includes a reservoir that may be loaded with the substance and a barrier located in relation to the reservoir such that substance that has been loaded into the reservoir will pass out of the reservoir and through the barrier at a known rate. A delivery catheter is advanceable through the guide catheter into the Eustachian tube and useable to deliver the implantable substance delivery device to the enlarged Eustachian tube.
A medical management system. The burdensome task of medication logging is greatly reduced for a patient when compared to conventional methods to perform these tasks. Moreover, the invention allows for pharmaceutical supplier/providers and healthcare providers the ability better to manage, track, and trend the medication and products that must be provided to patients. This integrated ability allows for better management of the inventory of highly perishable and life-saving medications for chronically ill patients. The invention also allows for highly accurate communication between patients and other parties including his/her medical doctor, a pharmaceutical supplier/provider who provides medications and products for the patient, as well as the insurance provider providing medical insurance coverage for the patient. The system integrates embedded functionality that ensures that in the accidental event that a patient is prescribed tainted medication, the patient is warned of the taint in due time before self-administering the medication to avoid potentially contracting a disease or other ailment from the tainted medication. Patient medication is tracked and trending over the lifetime of the medication and the treatment period for the patient. Exceptions that outlay the trending of the patient's medication are identified and properly communicated, sometimes automatically, to a healthcare provider or medical doctor who treats the patient. The system is adaptable for use generally or to treat specific diseases, such as chronic diseases as hemophilia, diabetes, asthma, HIV, and other diseases requiring long term treatment and ongoing administration of medications and products.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to curative agents used in traumatology and can be used for treatment of thermal, solar, chemical and infected burns of different severity degree, wounds of different etiology and freezing. The agent comprises perfluorodecaline and perfluorodimethylcyclohexane taken in the definite ratio of components. Invention provides accelerating processes of regeneration of impaired cells and wound epithelization, improves effectiveness against inflammatory processes, prevents appearance of rough scar tissue, excludes necessity of surgery operation and tissue transplantation and reduces times for treatment of patients. EFFECT: enhanced effectiveness of agent, valuable medicinal properties. 3 ex
BACKGROUND: Patients undergoing chimeric antigen receptor (CAR) T-cell therapy are vulnerable to infection and sepsis. Treatment course is frequently complicated by cytokine release syndrome which is often clinically and biochemically indistinguishable from sepsis. Procalcitonin (PCT) levels have been examined as a promising biomarker for infection in this cohort of patients.
METHODS: In this study, we measured daily PCT levels for patients for fourteen days (or hospital discharge) after receiving CAR T-cells to determine threshold PCT values specific for infection compared to those without infection.
RESULTS: We present preliminary results of our enrolled cohort to date (sixteen patients). Infection was present in only 12.5% of patients. However, those diagnosed with sepsis had elevated PCT levels with a peak mean of 2.6 µg/L observed on the seventh day post-treatment compared to those without infection remaining below 0.5 µg/L. Furthermore, we observed a trend for early and liberal antibiotic administration within our cohort.
CONCLUSION: Our study highlights the challenges of antimicrobial stewardship in managing CAR T-cell therapy recipients. Our preliminary results underscore the utility of PCT in the risk-stratification and diagnosis of those patients at high risk for infectious complications after receiving CAR T-cell therapy and continue to advocate for a PCT threshold of 1.5 µg/L for diagnosing sepsis. Additionally, in the setting of CRS and lymphodepletion, where white cell count and CRP value are unreliable, a PCT value of < 0.5 µg/L may help exclude sepsis.
The importance of the exercise and how it should be done were explained by the researcher Mixed teaching methods, including lecturing, demonstration, question-answer, and discussion were, used as education methods. The sessions were carried out online by a researcher who is an expert in the field of PRE for 30 minutes every day between 21:00 and 21:30 before bedtime for 30 days.
Standard of Care Docetaxel and Cyclophosphamide (TC) Chemotherapy + Surveys. TC Regimen with Function Assessment of Cancer Therapy (FACT) Surveys. All participants will receive TC for cycle 1 with subsequent cycles repeated every 3 weeks for a total of 4 cycles. All initial dosing will be based on actual body weight and height. Participants will receive up to 4 doses of chemotherapy. Following their 4th dose of chemotherapy, or the last dose of chemotherapy in which blood level monitoring was performed, participants will be assessed for side effects from the chemotherapy and complete their final written 53 question survey about their quality of life.
Acupressure is not provided, only general routines are performed. Pre-test and 3 post-tests of "Visual Analog Scale (VAS)", "5D Tickling Scale", and "Pittsburgh Sleep Quality Scale" are also required (week 4, week 8 and week 12).
Worldwide, cervical cancer is the fourth most common cancer among women, and the World Health Organization (WHO) Western Pacific Region, where the U.S.-affiliated Pacific Islands (USAPI) are located, accounts for one quarter of all estimated cases. Human papillomavirus (HPV) vaccines are recommended at age 11-12 years to prevent most cervical cancers. HPV vaccines were introduced across USAPI during 2007-2016, predominantly provided through school-located vaccination programs. Retrospective analysis using data from jurisdictional immunization information systems was used to estimate vaccination coverage among adolescent girls as of the last day of each calendar year during 2013-2023. This analysis measured progress toward the WHO 2030 vaccination coverage goal of ≥90% completion of the HPV vaccination series among girls by age 15 years. As of December 2023, initiation of the HPV vaccination series among adolescent girls aged 13-17 years ranged from 58.0% in Palau to 97.2% in the Northern Mariana Islands, and HPV vaccination series completion coverage ranged from 43.4% in Palau to 91.8% in the Northern Mariana Islands. HPV vaccination series completion coverage is >90% in the Northern Mariana Islands and is on track to meet WHO goals by 2030 in American Samoa. Assessment of adolescent vaccination coverage can help immunization programs monitor progress toward regional goals and identify populations and areas with low coverage. Implementing evidence-based strategies to increase vaccine access and coverage would benefit jurisdictions with lagging coverage.
Based on the mechanism of action, OFEV may increase the risk of gastrointestinal perforation. In IPF studies (Study 1, Study 2, and Study 3), gastrointestinal perforation was reported in less than 1% of patients treated with OFEV, compared to 0 cases in the placebo-treated patients. In the chronic fibrosing ILDs with a progressive phenotype study (Study 5), gastrointestinal perforation was not reported in any patients in any treatment arm. In the SSc-ILD study (Study 4), no cases of gastrointestinal perforation were reported in patients treated with OFEV or in placebo-treated patients.

In the postmarketing period, cases of gastrointestinal perforations have been reported, some of which were fatal. 

Use caution when treating patients who have had recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. Discontinue therapy with OFEV in patients who develop gastrointestinal perforation. Only use OFEV in patients with known risk of gastrointestinal perforation if the anticipated benefit outweighs the potential risk.
Disclosed are an A-FABP protein inhibitor and a use thereof, relating to the technical field of metabolic diseases, and cardiovascular and cerebrovascular complications thereof. Disclosed is an A-FABP protein inhibitor, an active ingredient of the A-FABP protein inhibitor being cobimetinib. The commercially available drug cobimetinib is used for targeted inhibition of the protein A-FABP. Pro-inflammatory biological activity of the protein A-FABP is inhibited by means of inhibiting phosphorylation of a JNK/c-Jun signaling pathway. Development of a novel use of an existing drug leads to significantly reduced costs of early-stage research and development and drastically reduced research and development period. Research results provide candidate medicines for various metabolic diseases.
One of the most common life-saving medical procedures is a red blood cell (RBC) transfusion. Unfortunately, RBCs for transfusion have a limited shelf life after donation due to detrimental storage effects on their morphological and biochemical properties. Inspired by nature, a biomimetics approach was developed to preserve RBCs for long-term storage using compounds found in animals with a natural propensity to survive in a frozen or desiccated state for decades. Trehalose was employed as a cryoprotective agent and added to the extracellular freezing solution of porcine RBCs. Slow cooling (-1 °C min-1) resulted in almost complete hemolysis (1 ± 1 % RBC recovery), and rapid cooling rates had to be used to achieve satisfactory cryopreservation outcomes. After rapid cooling, the highest percentage of RBC recovery was obtained by plunging in liquid nitrogen and thawing at 55 °C, using a cryopreservation solution containing 300 mM trehalose. Under these conditions, 88 ± 8 % of processed RBCs were recovered and retained hemoglobin (14 ± 2 % hemolysis). Hemoglobin's oxygen-binding properties of cryopreserved RBCs were not significantly different to unfrozen controls and was allosterically regulated by 2,3-bisphosphoglycerate. These data indicate the feasibility of using trehalose instead of glycerol as a cryoprotective compound for RBCs. In contrast to glycerol, trehalose-preserved RBCs can potentially be transfused without time-consuming washing steps, which significantly facilitates the usage of cryopreserved transfusible units in trauma situations when time is of the essence.
Mothers recieve a blister pack of zinc tablets in home every two months for use when child in home under 5 years has diarrhea. ORS satchets also given. Instructions on when and how to use zinc and ORS and when to take child in clinic are given by community health worker. Zinc will also be given in clinic if child visits clinic with diarrhea and has not yet started zinc at home.
PURPOSE:To prevent and improve pigmentation and enable continuous long-term use by using a pyrroloquinolinequinone ester excellent in melanin production inhibitory effect, melanization inhibitory effect and safety. CONSTITUTION:This melanin production inhibitor contains a pyrroloquinoline- quinone ester represented by formula I (R1 to R3 are each short chain alkyl, alkenyl, aralkyl, araaryl, phenyl or H and one or more of R1 to R3 are not H) or its salt as the active component. This melanin production inhibitor is used for a whitening dermal agent for external use. In this case, the content of the melanin production inhibitor is preferably 0.01 to 10wt.% based on the total amount of the agent for external use. As the pyrroloquinolinequinone ester of formula I, pyrrolo-quinolinequinone monoallyl ester of formula III is preferably used. This melanin production inhibitor and the inhibitor-containing whitening dermal agent for external use can be effectively utilized for prevention, improvement or therapy of local pigmentations and systemic pigmentations such as spot, freckle and sunburn.
Patients receive FOLFIRINOX for 4-6 months in the absence of disease progression or unacceptable toxicity. Patients may then undergo radiation therapy at the discretion of medical doctors.
Depending on the nature of their sports, athletes may be engaged in successive weight loss (WL) and regain, conducing to "weight cycling." The aims of this paper were to systematically (and meta-analytically when possible) analyze the post-WL recovery of (i) body weight and (ii) fat mass; fat-free mass; and performance and metabolic responses in weight cycling athletes (18-55 years old, body mass index < 30 kg.m-2 ). MEDLINE, Embase, and SPORTDiscus databases were explored. The quality and risk of bias of the 74 included studies were assessed using the quality assessment tool for quantitative studies. Thirty-two studies were eligible for meta-analyses. Whatever the type of sports or methods used to lose weight, post-WL body weight does not seem affected compared with pre-WL. While similar results are observed for fat-free mass, strength sports athletes (also having longer WL and regain periods) do not seem to fully recover their initial fat mass (ES: -0.39, 95% CI: [-0.77; -0.00], p = 0.048, I2  = 0.0%). Although the methods used by athletes to achieve WL might prevent them from a potential post-WL fat overshooting, further studies are needed to better understand WL episodes consequences on athletes' performance as well as short- and long-term physical, metabolic, and mental health.
Fracture healing is a complex biological process that involves the orchestrated interplay of various cells and molecular signaling pathways. Among the key players, macrophages have emerged as critical regulators of fracture repair, influencing inflammation, tissue remodeling, and angiogenesis. Recent advances in hydrogel-based therapeutics have provided exciting opportunities to leverage the modulatory effects of macrophages for improving fracture healing outcomes. In the present study, we review the importance of macrophages in fracture repair and their potential therapeutic role in hydrogel-based interventions. We discuss the molecular mechanisms underlying macrophage-mediated effects on fracture healing, and how hydrogels can be utilized as a platform for macrophage modulation. Furthermore, we highlight the translation of hydrogel-based therapies from bench to bedside, including preclinical and clinical studies, and the challenges and opportunities in harnessing the therapeutic potential of macrophages in fracture repair. Overall, understanding the importance of macrophages in fracture healing and the potential of hydrogel-based therapeutics to modulate macrophage responses can pave the way for developing innovative approaches to improve fracture healing outcomes.